期刊文献+

不同特征HIV阳性育龄女性抗苗勒氏管激素水平 被引量:1

Anti-Müllerian hormone levels in HIV-positive reproductive women with different characteristics
原文传递
导出
摘要 目的比较不同特征HIV阳性育龄女性抗苗勒氏管激素(AMH)水平,探讨HIV感染对女性卵巢功能的影响。方法检测不同特征的HIV阳性与HIV阴性育龄女性AMH水平,比较其差异。结果共715例HIV阳性育龄妇女(HIV阳性组)纳入研究,以同期接受体检的152例HIV阴性妇女作为对照(HIV阴性组),两组年龄构成差异无统计学意义(P>0.05)。HIV阳性18~30岁组和31~40岁组的AMH水平分别为5.8(3.2,10.6)ng/mL和3.5(1.8,7.0)ng/mL,前者明显高于后者(Z=-6.27,P=0.00);HIV阴性组18~30岁组和31~40岁组的AMH水平分别为7.4(4.2,10.0)ng/mL与3.8(2.4,6.4)ng/mL,前者也明显高于后者(Z=-4.78,P=0.00)。但HIV阳性和阴性受试者在同一年龄组的AMH水平比较差异无统计学意义(Z=-1.39,P=0.16;Z=-0.61,P=0.54)。同一年龄组的HIV阳性育龄妇女AMH水平,在是否接受ART,不同ART时长,不同ART方案,当前和治疗前HIV-1 RNA水平、CD4细胞计数和CD4/CD8比值间未见差异有统计学意义(P均>0.05)。结论不同年龄组育龄女性AMH水平有明显差别,但未见HIV感染及其他特征对AMH水平的影响,有待前瞻性研究进一步验证。 Objective To compare the serum anti-Mullerian hormone(AMH)level in HIV-positive reproductive women with different characteristics and explore the impact of HIV infection on ovarian function.Methods The serum AMH levels of reproductive age females,including HIV-positive and HIV-negative women,with 18-40 years old,without the gynecological disease,opportunistic infection,and tumor were tested.Meanwhile,these hormone levels in different subgroups classified by various factors were compared.Results A total of 715 HIV-positive healthy women of childbearing age(HIV positive group)were included in the study.152 HIV-negative healthy women of childbearing age who received a physical examination in the same period were taken as the control group(HIV negative group).The group was divided into two subgroups at the age of 30,including age stratification of 18-30 and 30-40.There was no statistical difference in the age between different subgroups(P>0.05).The AMH levels in HIV positive subgroups aged 18-30 and 31-40 were 5.8(3.2,10.6)ng/mL and 3.5(1.8,7.0)ng/mL,respectively,the former was significantly higher than the latter(z=-6.27,P=0.00);the AMH levels of HIV negative subgroups aged 18-30 and 31-40 were 7.4(4.2,10.0)ng/mL and 3.8(2.4,6.4)ng/mL,the former was also significantly higher than the latter(z=-4.78,P=0.00).However,there was no significant difference in AMH level between HIV positive and HIV negative subjects(z=-1.39,P=0.16;Z=-0.61,P=0.54).Moreover,in the same age subgroup,the serum AMH level did not change significantly regardless of the ART history,ART duration and regimen,HIV-1 RNA level,baseline CD4+count and CD4+/CD8+ratio,current CD4+count,and CD4+/CD8+ratio after ART(all P>0.05).Conclusion This study suggests that HIV infection and its different characteristics have no significant effect on AMH level in women of childbearing age,which needs to be further verified by prospective studies.
作者 宫丹丹 李丽雅 吴跃 李永红 温春燕 李虹 蔡卫平 李凌华 GONG Dandan;LI Liya;WU Yue;LI Yonghong;WEN Chunyan;LI Hong;CAI Weiping;LI Linghua(Infectious Disease Center,Guangzhou Eighth People's Hospital,Guangzhou 510060,China)
出处 《中国艾滋病性病》 CAS CSCD 北大核心 2021年第5期515-518,共4页 Chinese Journal of Aids & STD
基金 国家“十三五”科技重大专项课题(2018ZX10302103-002,2017ZX10202102-003-004,2017ZX10202101-003-001) 广州市科技创新委员会健康医疗协同创新重大计划课题(201803040002)。
关键词 艾滋病病毒 抗苗勒氏管激素/苗勒氏管抑制素 抗病毒治疗 细胞免疫功能 Human immunodeficiency virus(HIV) Anti-Müllerian hormone(AMH) Antiviral therapy(ART) Cellular immune function
  • 相关文献

参考文献2

二级参考文献26

  • 1赵晓明,毛宇红,刘芳荪,孙赟,洪燕,林其德.卵巢储备功能测定在体外受精(IVF)技术中的临床价值探讨[J].生殖与避孕,2005,25(8):465-468. 被引量:13
  • 2Long WQ, Ranchin V, Pautier P, et al. Detection of minimal levels of serum anti-miillerian hormone during follow-up of patients with ovarian granulosa cell tumor by means of a highly sensitive enzyme-linked immunosorbent assay. J Clin Endocrinol Metab, 2000, 85(2):540-4.
  • 3Seifer DB, MacLaughlin DT, Christian BP, et al. Early follicular serum miillerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles. Fertil Steril, 2002, 77(3): 468-71.
  • 4Kansal Kalra S, Ratcliffe S, Gracia CR, et al. Randomized controlled pilot trial of luteal phase recombinant FSH stimulation in poor responders. Reprod Biomed Online, 2008, 17 (6):745-50.
  • 5Golan A, Ron-EI R, Herman A, et al. OHSS: an update review. Obstet Gynecol Surv,1989, 44(6):430-40.
  • 6Deffieux X, Antoine JM. Inhibins, activins and anti Mullerian hormone: structure, signalling pathways, roles and predictive value in reproductive medicine. Gynecol Obstet Fertil, 2003, 31(11):900-11.
  • 7Rajpert-DeMeyts E, Jorgensen N, Graem N, et al. Expression of anti-Mtillerian hormone during normal and pathological gonadal development association with differentiation of Sertoli and granulose cells. J Clin Endocrinol Metah, 1999, 84 (10):3836-44.
  • 8Baarends WM, Uilenbroek JT, Kramer P. Anti-mullerian hormone and anti-mullerian hormone type II receptor messenger ribonucleic acid expression in rat ovaries during postnatal development,the estrous cycle, and gonadotropin-induced follicle growth. Endocrinology, 1995, 136(10):4951-62.
  • 9Hazout A, Bouchard P, Seifer DB, et al. Serum antimullerian inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone, inhibin B, or estradiol. Fertil Steril, 2004, 82(5): 1323-9.
  • 10Gnoth C, Schuring AN, Friol K, et al. Relevance of anti-Mullerian hormone measurement in a routine IVF program. Hum Reprod, 2008, 23(6): 1359-65.

共引文献251

同被引文献10

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部